Market Overview

12 Biggest Mid-Day Losers For Monday



  • Dynavax Technologies Corporation (NASDAQ: DVAX) shares tumbled 64.9 percent to $4.07 after the disclosure of a Complete Response Letter (CRL) from the FDA on its Biologics License Application for HEPLISAV-B. The drug candidate is meant for immunization of adults 18 years and older affected by hepatitis B infection.
  • Resource Capital Corp. (NYSE: RSO) shares declined 27.7 percent to $8.80. Resource Capital reported Q3 funds from operations of $12.9 million, or $42 per share.
  • Puma Biotechnology Inc (NYSE: PBYI) shares fell 22.3 percent to $39.15 on Friday's KSF investigation into the company.
  • Turtle Beach Corp (NASDAQ: HEAR) dropped 21.2 percent to $1.52. B. Riley downgraded Turtle Beach from Buy to Neutral.
  • JetPay Corporation (NASDAQ: JTPY) declined 15.1 percent to $2.25. JetPay reported a Q3 loss of $0.16 per share on revenue of $15.21 million.
  • Net Element International Inc (NASDAQ: NETE) shares fell 13.7 percent to $0.950. Net Element reported Q3 adjusted loss of $0.20 per share on revenue of $14.01 million.
  • Patriot National Inc (NYSE: PN) declined 13.2 percent to $5.94. Patriot National posted Q3 earnings of $0.12 per share on revenue of $60.2 million.
  • Galena Biopharma Inc (NASDAQ: GALE) dropped 12.4 percent to $3.68 after the company disclosed that data from GALE-301/GALE-302 clinical program was presented at the Society for Immunotherapy of Cancer Conference 2016.
  • NetSol Technologies Inc. (NASDAQ: NTWK) fell 12.2 percent to $5.40. NETSOL posted a Q1 loss of $0.17 per share on revenue of $15 million.
  • Gold Standard Ventures Corp (NYSE: GSV) shares declined 11.2 percent to $1.91. Gold Standard Ventures shares have jumped 298.15 percent over the past 52 weeks, while the S&P 500 index has gained 5.42 percent in the same period.
  • Edgewater Technology Inc. (NASDAQ: EDGW) dropped 10.4 percent to $7.17 as the company reported the conclusion of formal review of strategic alternatives.
  • Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) declined 3.7 percent to $79.03. Citigroup downgraded Ultragenyx Pharmaceutical from Neutral to Sell.

Posted-In: Mid-Day LosersNews Movers & Shakers Intraday Update Markets


Related Articles (DVAX + EDGW)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Here's Every Sell-Side Rating Following iRhythm's IPO Quiet Period Expiration

Technical Alert: Amazon Nears $700